Prof. Moshe Elkabets

Prof. Moshe Elkabets Profile

Associate Professor
PhD 2009

Department : Shraga Segal Department of Microbiology, Immunology and Genetics
Room : 224
בנין מעבדות מחקר רפואה ע"ש דייכמן - פלאם - M6
Phone : 972-8-6479291
Email :
Office Hours :  
Cancer genomics and therapy


B.Med.Sc.L 2000-2003, Ben-Gurion University , Medical laboratory.
M.Sc. 2003-2005, Ben-Gurion University, Faculty of health Sciences, Department of Immunology and Microbiology. Advisors: Profs Ronnie Apte and Shraga Segal
Ph.D 2005-2009, Ben-Gurion University, Faculty of health Sciences, Department of Immunology and Microbiology. Advisor: Prof. Ronnie Apte
Post-Doctoral 2010-2011, Brigham and Women’s Hospital, Harvard Medical School, Department of Hematology. Advisor: Dr. Sandra McAllister
Post-Doctoral 2011-2015, Massachusetts General Hospital, Harvard Medical School (Boston, MA, USA) and Memorial Sloan Kettering Cancer Center (NY, NY, USA).Department of Human Oncology and Pathology Advisor: Dr. Jose Baselga

Research Topics

  • Mechanisms of resistance to targeted therapies and investigate novel therapeutic strategies in head and neck cancer.
  • Develop unique cancer models in mice to study the role of the tumor microenvironment in response to therapy.Study the interface between immunotherapy and cancer genomics.

Major expertise and techniques in the lab

  • Molecular biology and Biochemistry
  • Pathology and imaging
  • Mouse models and Immunological assays

Publications and funding summary / representative publications and grants

Elkabets M., Pazarentzos E., Sheng Q., Pelossof R.A., Brook S., Morse N., Yan JJ., Liu M., Das R., Chen Y., Tam A., Wang H., Liang J., Huang A., Ghissein RA., Rosen N., Bivona T.G., Scaltriti M., Baselga J. AXL mediates resistance to PI3K?†inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 2015 April

Elkabets M.*, Vora S.*, Juric D., Morse N., Mino-Kenudson M., Muranen T., Tao J., Campos AB., Rodon J., Ibrahim YH., Serra V., Rodrik-Outmezguine V., Hazra S., Singh S., Kim P., Quadt C., Liu M., Huang A., Rosen N., Engelman JA., Scaltriti M., Baselga J. mTORC1 inhibition is required for sensitivity to PI3K p110?†inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 2013 Jul. *Equal Contribution.

Elabets M.*, Gifford AG.*, Scheel C., Nilsson B., Reinhardt F., Bray MA., Carpenter AE., Jirstr?m K., Magnuson K., Ebert BL., Pont?n F.,. Weinberg RA., McAllister SS. Human Tumors Instigate Granulin-Expressing Hematopoietic Cells that Promote Malignancy by Activating Stromal Fibroblasts in Mice. J Clin Invest. 2011 Feb *Equal Contribution.

Existing collaborations

  • Jose Baselga – MSKCC, NY, USA
  • Aron Popvtzer- Belinson
  • Novartis – MA, USA